Public Employees Retirement System of Ohio Invests $7.26 Million in Moderna, Inc. $MRNA

Public Employees Retirement System of Ohio bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, HoldingsChannel reports. The fund bought 103,730 shares of the company’s stock, valued at approximately $7,264,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRNA. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the 2nd quarter worth about $28,000. Allied Private Wealth LLC acquired a new stake in shares of Moderna during the 2nd quarter worth about $30,000. Canton Hathaway LLC purchased a new stake in Moderna during the first quarter worth approximately $31,000. EverSource Wealth Advisors LLC lifted its stake in Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after purchasing an additional 208 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRNA has been the topic of a number of research analyst reports. Citigroup raised their price objective on shares of Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Barclays boosted their price target on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research note on Friday. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group raised their price objective on Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $80.53.

Moderna Trading Up 9.9%

NASDAQ MRNA opened at $154.27 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The firm has a market cap of $61.59 billion, a PE ratio of -19.31 and a beta of 1.09. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The firm’s fifty day moving average is $80.59 and its two-hundred day moving average is $61.34.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the prior year, the firm earned ($2.13) earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by corporate insiders.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive late-stage results from Moderna and Merck’s personalized melanoma vaccine remain the primary catalyst. The data reinforced expectations that Moderna can expand beyond COVID-19 vaccines into cancer immunotherapy and potentially create a significant long-term revenue stream. Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
• Positive Sentiment: Options activity was notably bullish, with investors purchasing 106,605 call contracts—about 35% above typical volume. The activity suggests increased speculative interest in further gains, although options positioning can also amplify volatility.
• Positive Sentiment: Moderna’s updated COVID-19 vaccine approvals and the company’s recent momentum have helped restore investor confidence in its commercial and regulatory execution. Shares more than doubled during August, making the stock one of the market’s strongest performers. Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
• Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23. These events could provide updates on the oncology pipeline, vaccine demand and the path to profitability, but no new financial information was announced. Moderna to Present at Upcoming Conferences in September 2026
• Negative Sentiment: GSK advanced its competing mRNA influenza vaccine into a Phase III trial, increasing future competitive pressure shortly after Moderna received approval for the first seasonal flu mRNA vaccine. Investors appear to be treating the threat as manageable for now, with greater emphasis on Moderna’s cancer program. GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
• Negative Sentiment: Brookline Capital Markets modestly reduced its FY2029 and FY2030 EPS estimates, while maintaining a Buy rating. The cuts signal limited near-term financial visibility as Moderna remains loss-making and analysts expect a full-year loss.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.